kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
4,601
JPY
-80
(-1.71%)
Jan 15, 3:30 pm JST
29.01
USD
Jan 15, 1:30 am EST
Result
PTS
outside of trading hours
4,616
Jan 15, 11:44 pm JST
Summary Chart Historical News Financial Result
PER
31.2
PBR
1.52
Yield
3.48%
Margin Trading Ratio
19.70
Stock Price
Jan 15, 2026
Opening Jan 15, 9:00 am
4,655 JPY 29.38 USD
Previous Close Jan 14
4,681 JPY 29.38 USD
High Jan 15, 9:00 am
4,659 JPY 29.40 USD
Low Jan 15, 9:16 am
4,590 JPY 28.95 USD
Volume
1,668,000
Trading Value
7.70B JPY 0.05B USD
VWAP
4617.92 JPY 29.13 USD
Minimum Trading Value
460,100 JPY 2,901 USD
Market Cap
1.34T JPY 8.49B USD
Number of Trades
4,072
Liquidity & Number of Trades
As of Jan 15, 2026
Liquidity
High
1-Year Average
3,657
1-Year High May 15, 2025
11,589
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 9, 2026 64,900 1,629,200 25.10
Dec 26, 2025 60,600 1,705,300 28.14
Dec 19, 2025 52,100 1,908,300 36.63
Dec 12, 2025 62,600 1,849,200 29.54
Dec 5, 2025 65,000 1,742,600 26.81
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.